{"filing":{"accession_number":"0001193125-26-354026","cik":"0001437402","ticker":"ARDX","company_name":"ARDELYX, INC.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-11","primary_document":"d921015d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1437402/000119312526354026/d921015d8k.htm"},"events":[{"id":28232,"run_id":25813,"accession_number":"0001193125-26-354026","anchor_item_number":"8.01","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Eric Foster, Chief Commercial Officer, notified the Company on August 11, 2026 of his resignation effective August 28, 2026. The disclosure centers on a named executive's departure from the Company. While disclosed under Item 8.01 (Other Events) rather than the typical Item 5.02, the substance is clearly an executive departure, and the CCO role is material to a commercial-stage biopharmaceutical company.","company_name":"ARDELYX, INC.","ticker":"ARDX","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":30110,"accession_number":"0001193125-26-354026","item_number":"8.01","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Eric Foster, Chief Commercial Officer, notified the Company on August 11, 2026 of his resignation effective August 28, 2026. The disclosure centers on a named executive's departure from the Company. While disclosed under Item 8.01 (Other Events) rather than the typical Item 5.02, the substance is clearly an executive departure, and the CCO role is material to a commercial-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:06:51.822639+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30110,"accession_number":"0001193125-26-354026","item_number":"8.01","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Eric Foster, Chief Commercial Officer, notified the Company on August 11, 2026 of his resignation effective August 28, 2026. The disclosure centers on a named executive's departure from the Company. While disclosed under Item 8.01 (Other Events) rather than the typical Item 5.02, the substance is clearly an executive departure, and the CCO role is material to a commercial-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:06:51.822639+00:00","company_name":"ARDELYX, INC.","ticker":"ARDX","filing_date":"2026-08-17"}]}